<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513955</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000559820</org_study_id>
    <secondary_id>NCRN-Ply-26s</secondary_id>
    <secondary_id>EU-20747</secondary_id>
    <secondary_id>ISRCTN200600609024</secondary_id>
    <nct_id>NCT00513955</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma</brief_title>
  <official_title>A Parallel Randomised Phase II Trial of CHOP Chemotherapy With or Without Bortezomib in Relapsed Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Plymouth NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Plymouth NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine,&#xD;
      and prednisolone, work in different ways to stop the growth of cancer cells, either by&#xD;
      killing the cells or stopping them from dividing. Bortezomib may stop the growth of cancer&#xD;
      cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy&#xD;
      together with bortezomib may kill more cancer cells. It is not yet known whether combination&#xD;
      chemotherapy is more effective with or without bortezomib in treating mantle cell lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying combination chemotherapy and bortezomib&#xD;
      to see how well they work compared with combination chemotherapy alone in treating patients&#xD;
      with relapsed or refractory mantle cell lymphoma. Combination chemotherapy alone (Arm I) has&#xD;
      been discontinued April 2012 on recommendation of the DMC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the rates of overall response (complete response [CR], CR unconfirmed [CRu],&#xD;
           and partial response).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the rates of CR and CRu.&#xD;
&#xD;
        -  To determine the median time to progression.&#xD;
&#xD;
        -  To determine the median overall survival.&#xD;
&#xD;
        -  To evaluate the toxicity and tolerability.&#xD;
&#xD;
        -  To compare the responses to these treatment regimens with those from first line therapy.&#xD;
&#xD;
        -  To compare the quality of life.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, parallel group, multicenter study. Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (CHOP): Patients receive doxorubicin hydrochloride IV, cyclophosphamide IV, and&#xD;
           vincristine IV on day 1 and oral prednisolone on days 1-5. Arm I has been discontinued&#xD;
           April 2012 on recommendation of the DMC.&#xD;
&#xD;
        -  Arm II (CHOP with bortezomib): Patients receive bortezomib IV over 3-5 seconds on days 1&#xD;
           and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1;&#xD;
           and oral prednisolone on days 1-5.&#xD;
&#xD;
      In both arms, treatment repeats every 21 days for up to 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients complete quality of life questionnaires at baseline, prior to each treatment course,&#xD;
      and then at 30 days after completion of treatment.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 30 days and then every 12 weeks&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>30 days and every 12 weeks</time_frame>
    <description>The follow-up visits will be at 30 days after last dose of study drug and after that every 12 weeks until: Progressive disease, initiation of further anti-neoplastic therapy, patient decision to withdraw from the study, patient death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unacceptable toxicity or tolerability as assessed by NCI CTCAE v3.0</measure>
    <time_frame>continual after first drug dose</time_frame>
    <description>The follow-up visits will be at 30 days after last dose of study drug and after that every 12 weeks until: Progressive disease, initiation of further anti-neoplastic therapy, patient decision to withdraw from the study, patient death.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1 and 8; doxorubicin hydrochloride IV, cyclophosphamide IV, and vincristine IV on day 1; and oral prednisolone on days 1-5.&#xD;
Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients complete quality of life questionnaires at baseline, prior to each treatment course, and then at 30 days after completion of treatment.&#xD;
After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <arm_group_label>Bortezomib plus CHOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of mantle cell lymphoma (MCL)&#xD;
&#xD;
               -  Expression of cyclin D1 or evidence of t(11;14) translocation by cytogenetics,&#xD;
                  FISH, or polymerase chain reaction&#xD;
&#xD;
          -  Refractory to or relapsed or progressed after first line antineoplastic therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Karnofsky performance status (PS) 50-100% OR ECOG PS 0-2&#xD;
&#xD;
          -  ANC ≥ 1,000/mm³ (not related to lymphoma)&#xD;
&#xD;
          -  Platelet count ≥ 30,000/mm³&#xD;
&#xD;
          -  AST and ALT ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin ≤ 2 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 20 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Known serological positivity for HBV, HCV, or HIV&#xD;
&#xD;
          -  History of allergic reaction attributable to compounds containing boron or mannitol&#xD;
&#xD;
          -  Diagnosed or treated for a malignancy other than MCL within the past 5 years except&#xD;
             for completely resected basal cell or squamous cell carcinoma of the skin or any in&#xD;
             situ malignancy&#xD;
&#xD;
          -  Active systemic infection requiring treatment&#xD;
&#xD;
          -  Serious medical or psychiatric illness that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Toxic effects of prior therapy or surgery must be resolved to ≤ grade 2&#xD;
&#xD;
          -  Prior splenectomy or localized radiotherapy allowed&#xD;
&#xD;
          -  Any prior chemotherapy regimen allowed&#xD;
&#xD;
               -  Chemotherapy may have been given in combination with rituximab&#xD;
&#xD;
          -  Concurrent enrollment in a nontreatment study allowed, provided it does not interfere&#xD;
             with participation in this study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior bortezomib&#xD;
&#xD;
          -  Antineoplastic therapy within the past 3 weeks&#xD;
&#xD;
          -  Nitrosoureas within the past 6 weeks&#xD;
&#xD;
          -  Rituximab, alemtuzumab (Campath®), or other unconjugated therapeutic antibody within&#xD;
             the past 4 weeks&#xD;
&#xD;
          -  Radiotherapy within the past 3 weeks&#xD;
&#xD;
          -  Major surgery within the past 2 weeks&#xD;
&#xD;
          -  Concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Rule, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Derriford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Hope Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B75 7RR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <state>England</state>
        <zip>FY3 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <state>England</state>
        <zip>DA2 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>England</state>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Kent Oncology Centre at Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>England</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Paget Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>England</state>
        <zip>NR31 6LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>England</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>England</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital</name>
      <address>
        <city>Prescot Merseyside</city>
        <state>England</state>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunderland Royal Hospital</name>
      <address>
        <city>Sunderland</city>
        <state>England</state>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Musgrove Park Hospital</name>
      <address>
        <city>Taunton</city>
        <state>England</state>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Torbay Hospital</name>
      <address>
        <city>Torquay</city>
        <state>England</state>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro, Cornwall</city>
        <state>England</state>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raigmore Hospital</name>
      <address>
        <city>Inverness</city>
        <state>Scotland</state>
        <zip>1V2 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ysbyty Gwynedd</name>
      <address>
        <city>Bangor</city>
        <state>Wales</state>
        <zip>LL57 2PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Philip Hospital</name>
      <address>
        <city>Llanelli</city>
        <state>Wales</state>
        <zip>SA14 8QF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol. 2015 Jan;168(1):55-62. doi: 10.1111/bjh.13101. Epub 2014 Aug 22.</citation>
    <PMID>25146720</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>August 8, 2007</study_first_submitted>
  <study_first_submitted_qc>August 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2007</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

